echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 2016 China's top 20 most competitive pharmaceutical listed companies

    2016 China's top 20 most competitive pharmaceutical listed companies

    • Last Update: 2016-09-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: on September 1, 2016, e-medicine manager experienced economic downturn, capital market turbulence, and drastic changes in medical reform policies, all of which pointed to the fact that the pharmaceutical industry is ushering in its bad era The 8th top 20 most competitive pharmaceutical listed companies in China have officially come out The most competitive companies have the common characteristics that they are able to cope with, change and resist risks no matter what the environment they are in 2015 is a year of deepening reform in the pharmaceutical industry, which has been promoted from the ministerial level to the national strategic level The rapid and violent reform is reflected in every pharmaceutical listed company, which can best reflect its ability to cope with environmental changes and resist risks So, who is the competitive enterprise, who is the nude swimmer after the spring tide? It is believed that many people have a good understanding of the performance of pharmaceutical stocks in 2015 In the bull market, a large number of enterprises are one step away from the market value of 100 billion yuan However, only the enterprises represented by Hengrui pharmaceutical keep up and enter the era of 100 billion yuan market value Hengrui can keep the same posture when the capital market changes face, because Hengrui medicine represents the highest level of Chinese pharmaceutical research and development Open the list of the top 20 most competitive pharmaceutical listed companies in 2016 (the eighth session) Compared with the list in the past few years, the change is the entry or exit of some enterprises What's unchanged is that only in the changing situation, moving against the trend, is the ultimate holder of competitiveness Therefore, it's no surprise that Hengrui medicine won the championship in a row Three years ago, it was No 9 in the top 20 list of competitiveness The industry is returning to the essence of pharmaceutical development, and R & D and innovation are awakening At the same time, the tide of going out of the sea is surging, and some enterprises highlight their competitiveness through M & A, especially those capital experts who are good at medicine have focused on the global market For example, Fosun medicine and humanwell medicine have made a lot of money in the past year In addition, Yunnan Baiyao, Tianshili and other enterprises rely on the original strength to explore new models for future development 1 The awakening of innovation goes back three years When pharmaceutical enterprises talk about their core competitiveness, they will talk about R & D, marketing, corporate culture, management system and other fields But now many enterprises start to talk about R & D, and now the pharmaceutical industry has reached an era of embarrassment without talking about innovation Peter Drucker said: if you don't innovate, you die Although this sentence is put in the current Chinese pharmaceutical enterprises or too alarmist, if you look closely at the top 20 competitive enterprises, it is not difficult to find that most of them rely on a single original research product to support their business income and profits in the past years Hengrui medicine has risen so fast in recent years, and it can keep it, because Hengrui medicine has changed from 2000 In, he realized that the homogenization competition in China's pharmaceutical industry would be severe, and began to put forward innovation strategies After that, he devoted himself to building a research and development system, and carried out research and development step by step After more than ten years of stealth, his accumulated research and development strength began to thin, and the competitive edge became increasingly prosperous, becoming the research and development leader of the industry In September last year, Hengrui pharmaceutical reached an agreement with Incyte company of the United States to license the PD-1 monoclonal antibody project for tumor treatment with independent intellectual property rights to the latter for a fee The sale of the drug's overseas interest earned it $795 million This not only proves the actual level of R & D, but also shows the charm of R & D for pharmaceutical enterprises As we all know, R & D is a kind of slow work, which is neither quick nor urgent But for the local companies who want to achieve great pharmaceutical enterprises, the layout of R & D is an unavoidable obstacle Because the ammunition for enterprises to win the market is products, and the competitiveness of products is more reflected in innovation ability Shiyao group is the exploratory flower in this year's competitiveness list It does not have the same obvious R & D and innovation label as Hengrui medicine, but it is also developing towards R & D and innovation oriented enterprises Around 2012, Shiyao group began to implement strategic transformation, from the upgrading of API manufacturers to innovative and brand medicine manufacturers Since then, brand medicine and innovative medicine businesses not included in the listed companies have been injected into the listed companies In 2013, they were listed in the top 20 competitive companies Among them, the sales of new drugs enbip reached 680 million yuan, olanin 450 million yuan and Xuanning 165 million yuan Billion yuan, becoming the profit cow of the listed company, has also changed the image that the group is only good at selling APIs, and this listing also has a significant relationship with the continuous development of innovative drugs In recent years, Shiyao group, which has enjoyed the benefits of innovation, has begun to make a big contribution to research and development, spending about 11% of its innovative drug revenue in recent years on research and development It is understood that Shiyao group currently has 180 kinds of products under research, involving many fields such as cardio cerebrovascular, diabetes, anti-tumor and so on, including 14 national first-class new drugs and 51 third class new drugs In addition to the pioneers of Hengrui pharmaceutical, Shiyao group, and xinlitai who have been in the harvest period for many years, there are also some enterprises such as Huadong pharmaceutical and Lizhu group that rely on existing resources to carry out innovative R & D layout, such as Lizhu group raised 14.6 last year Billion yuan is used in the in-depth development and industrial upgrading projects of innovative products of iprazole series, the R & D and industrial construction projects of antibody drugs for treatment, etc Although the main data for the selection of the top 20 competitiveness companies is the business indicators in 2015, the market value performance and industry experts' scoring mainly focus on their future development trend Therefore, enterprises like Lizhu with hot R & D layout are new faces, but the industry has obviously felt the formation of their R & D strength  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.